Q-omics provides the consensus-scored OR56B2P profile across patient tissues and cancer cell-line models. OR56B2P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, OR56B2P is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, OR56B2P RNA expression shows 10,087 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, LUSC, and TGCT as cancer lineages where OR56B2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR56B2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR56B2P survival associations across molecular data types. OR56B2P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR56B2P RNA expression–survival associations across cancer types. High OR56B2P expression shows unfavorable associations in UCS, DLBC, UCEC and COAD, but favorable associations in ESCA and BRCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for OR56B2P RNA expression.
This table summarizes OR56B2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR56B2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR56B2P shows lower tumor expression in LUSC, UCEC, BRCA and KIRP. The LUSC box plot shows higher OR56B2P RNA expression in normal versus tumor tissue (log2 FC = −0.052, t-test p = .003).
This table shows molecular features associated with OR56B2P in patient tissues and cancer cell lines. In patient samples, OR56B2P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
